Beta

Quantum biopharma ltd.QNTM.US Overview

US StockHealthcare
(No presentation for QNTM)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

QNTM AI Insights

QNTM Overall Performance

QNTM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

QNTM Recent Performance

20.67%

Quantum biopharma ltd.

-1.10%

Avg of Sector

-0.49%

S&P500

QNTM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check QNTM's Trend

QNTM Key Information

QNTM Valuation Metrics

QNTM Profile

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

Price of QNTM

QNTM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

QNTM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
91.86
PB Ratio
3.04
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
91.86
PB Ratio
3.04
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is QNTM's latest earnings report released?

    The most recent financial report for Quantum biopharma ltd. (QNTM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating QNTM's short-term business performance and financial health. For the latest updates on QNTM's earnings releases, visit this page regularly.

  • How much cash does QNTM have?

    At the end of the period, Quantum biopharma ltd. (QNTM) held Total Cash and Cash Equivalents of 1.91M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is QNTM's EPS continuing to grow?

    According to the past four quarterly reports, Quantum biopharma ltd. (QNTM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.71. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of QNTM?

    Quantum biopharma ltd. (QNTM)'s Free Cash Flow (FCF) for the period is -4.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 446.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of QNTM?

    The latest valuation data shows Quantum biopharma ltd. (QNTM) has a Price-To-Earnings (PE) ratio of -0.79 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.